AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
LifeVantage CEO and CFO to Present at Lytham Partners Fall 2025 Investor Conference on September 30, 2025.
ByAinvest
Monday, Sep 22, 2025 8:08 am ET1min read
LifeVantage Corporation, a health and wellness company, announced that CEO Steve Fife and CFO Carl Aure will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. They will present virtually at approximately 11:00 a.m. Eastern Time. A live webcast of their presentation will be available on the company's website.
LifeVantage Corporation (NASDAQ: LFVN) has announced that its CEO, Steve Fife, and CFO, Carl Aure, will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The virtual presentation will take place at approximately 11:00 a.m. Eastern Time and will be available via a live webcast on the company's website.The Lytham Partners Fall 2025 Investor Conference is a prominent event where companies present their business strategies, financial performance, and future prospects to investors and financial professionals. LifeVantage's participation in this conference provides an opportunity for the company to engage with investors and provide insights into its operations and growth plans.
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The company's products include Protandim, LifeVantage Omega+, LifeVantage ProBio, PhysIQ, LifeVantage IC Bright, Petandim for Dogs, and Axio.
Recently, LifeVantage has seen increased institutional investment in its shares. Acadian Asset Management LLC raised its stake by 47.3% in the first quarter, while other institutional investors and hedge funds also added to their positions. This trend indicates growing confidence in the company's prospects [1].
In addition to its operational activities, LifeVantage has been proactive in its financial management. The company announced a quarterly dividend of $0.045 per share on September 16, 2025, representing an annualized dividend of $0.18 and a yield of 1.7% [1].
LifeVantage's stock has shown resilience despite market fluctuations. The stock traded down $0.27 during midday trading on September 12, 2025, hitting $10.63. The company's stock has a one-year low of $9.83 and a one-year high of $27.38 [1].
Investors and financial professionals are encouraged to tune in to the Lytham Partners Fall 2025 Investor Conference to gain insights into LifeVantage Corporation's strategies and future outlook.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet